Secukinumab 300 mg, s.c. + Prednisolone + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Giant Cell Arteritis
Conditions
Giant Cell Arteritis
Trial Timeline
Jan 30, 2019 → Jun 8, 2021
NCT ID
NCT03765788About Secukinumab 300 mg, s.c. + Prednisolone + Placebo
Secukinumab 300 mg, s.c. + Prednisolone + Placebo is a phase 2 stage product being developed by Novartis for Giant Cell Arteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT03765788. Target conditions include Giant Cell Arteritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03765788 | Phase 2 | Completed |
Competing Products
20 competing products in Giant Cell Arteritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| prednisone | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Pexidartinib | Daiichi Sankyo | Phase 2 | 52 |
| Pexidartinib | Daiichi Sankyo | Phase 3 | 77 |
| Pexidartinib | Daiichi Sankyo | Approved | 85 |
| Baricitinib | Eli Lilly | Phase 2 | 52 |
| Upadacitinib + Corticosteroid (CS) | AbbVie | Phase 3 | 77 |
| dovitinib | Novartis | Phase 2 | 52 |
| Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c. | Novartis | Phase 3 | 77 |
| Secukinumab | Novartis | Phase 1 | 33 |
| Secukinumab 300 mg + Secukinumab 150 mg | Novartis | Phase 3 | 77 |
| Tocilizumab + Placebo | Roche | Phase 3 | 77 |
| Tocilizumab + Prednisone | Roche | Approved | 85 |
| Tocilizumab | Roche | Phase 3 | 77 |
| Tocilizumab | Roche | Phase 1 | 33 |
| Valganciclovir | Roche | Approved | 85 |
| Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate | Roche | Phase 3 | 77 |
| Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs) | Roche | Phase 2 | 52 |
| tocilizumab and IV steroids combination | Roche | Phase 2 | 52 |
| Denosumab | Amgen | Approved | 84 |
| Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA] | Amgen | Phase 2 | 51 |